Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis.
BACKGROUND
The present study examined the effects of atorvastatin and the in vitro effect of apolipoprotein (apo) A-I/phosphatidylcholine (POPC) discs on charge-based triglyceride-rich lipoprotein (TRL) subfractions in a patient with type III hyperlipoproteinemia (HLP) and the apoE2/2 phenotype.


METHODS
Charge-based lipoprotein subfractions were characterized by capillary isotachophoresis (cITP). cITP analysis was performed using plasma that had been prestained with a lipophilic dye on a Beckman P/ACE MDQ system.


RESULTS
Treatment with atorvastatin for 4 weeks markedly decreased the slow (s)-migrating TRL subfraction and both fast- and slow-migrating low-density lipoprotein (LDL) subfractions, but did not affect the fast (f)-migrating TRL subfraction in this patient. ApoA-I/POPC discs consisted of two major charge-based subfractions that had the mobility of cITP fTRL and sTRL. Incubation of plasma from this patient in the presence of apoA-I/POPC discs caused not only a reduction in cITP fast- and intermediate-migrating HDL and an increase in cITP sHDL but also a reduction in fTRL and sTRL and an increase in sLDL.


CONCLUSIONS
Atorvastatin and apoA-I/POPC discs decreased cITP TRL subfractions in a complementary manner, suggesting that the combination of apoA-I/POPC discs and atorvastatin could be a promising therapeutic approach for hypertriglyceridemia.
Zhang
Bo
B
Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma Jonan-ku, Fukuoka 814-0180, Japan.
Katafuchi
Ritsuko
R
Arishima
Hiroaki
H
Matsunaga
Akira
A
Rye
Kerry-Anne
KA
Saku
Keijiro
K
D000328:Adult; D016632:Apolipoprotein A-I / Q000737:chemistry* / Q000494:pharmacology; D053329:Apolipoprotein E2 / Q000235:genetics; D000069059:Atorvastatin; D019075:Electrophoresis, Capillary / Q000379:methods; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008074:Lipoproteins / Q000097:blood / Q000737:chemistry* / Q000187:drug effects; D046911:Macromolecular Substances / Q000737:chemistry / Q000494:pharmacology; D008297:Male; D010641:Phenotype; D010713:Phosphatidylcholines / Q000737:chemistry* / Q000494:pharmacology; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D013997:Time Factors; D014280:Triglycerides / Q000032:analysis*
D016632:Apolipoprotein A-I; D053329:Apolipoprotein E2; D006538:Heptanoic Acids; D008074:Lipoproteins; D046911:Macromolecular Substances; D010713:Phosphatidylcholines; D011758:Pyrroles; D014280:Triglycerides; D000069059:Atorvastatin